Review of price tag for Spark Therapeutics’ gene therapy treatment (Luxturna, $850,000 per patient) suggests a discount of up to 90% in certain cases.
In a report published by the US Institute for Clinical and Economic Review (ICER), healthcare experts stated that the recently approved gene therapy for Leber’s congenital amaurosis (LCA), “Luxturna voretigene neparvovec-rzyl”, from Spark Therapeutics Inc. (NASDAQ:ONCE), may require substantial discounts in order to be cost-effective. The new drug, developed by Spark Therapeutics, a gene therapy […]Read full story
Biomarkers of metabolism, easily detectable with SD-OCT, indicate association with successful treatment of DME with DEX implant.
Collaborative clinical research by clinicians based in Tel Aviv University, Israel, University of Buenos Aires, Argentina, the University of Leipzig, Germany and the University of Milan, Italy have shown that certain SD-OCT biomarkers may act as useful image findings pointers in DEX treatment of diabetic macular edema (DME). The research, carried out on a total […]Read full story
CRISPR / Cas 9 gene editing technology shows promising anti-VEGF affects in lab models of angiogenesis.
Researchers, led by investigators at the Schepens Eye Research Institute of Massachusetts Eye and Ear, and the Department of Ophthalmology, Harvard Medical School, Boston, have shown that recently developed gene editing technology is capable of depleting VEGF2 expression demonstrating a potential therapeutic approach to retinal angiogenesis. The technology, commonly referred to as CRISPR / Cas […]Read full story